OptiNose (OPTN) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free OPTN Stock Alerts $1.17 -0.05 (-4.10%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 11:02 PM | ca.finance.yahoo.comOptiNose, Inc. (OPTN) Stock Price, News, Quote & History - Yahoo FinanceMay 12 at 6:48 AM | msn.comOptinose to Unveil First Quarter 2024 Financial Results and UpdatesMay 12 at 3:20 AM | americanbankingnews.comOptiNose (OPTN) Scheduled to Post Earnings on TuesdayMay 11 at 8:37 AM | marketbeat.comOptiNose (OPTN) Set to Announce Earnings on TuesdayOptiNose (NASDAQ:OPTN) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 10, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Announces $55 Million Financing Round Amidst Revenue ProjectionsMay 10, 2024 | globenewswire.comOptinose Announces Reporting Date for First Quarter 2024 Financial ResultsMay 9, 2024 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on Optinose (OPTN)May 9, 2024 | finance.yahoo.comOptinose Announces $55 Million Registered Direct OfferingMay 5, 2024 | finance.yahoo.comRecent uptick might appease OptiNose, Inc. (NASDAQ:OPTN) institutional owners after losing 50% over the past yearMay 1, 2024 | marketbeat.comQ1 2024 EPS Estimates for OptiNose, Inc. Increased by Analyst (NASDAQ:OPTN)OptiNose, Inc. (NASDAQ:OPTN - Free Report) - HC Wainwright raised their Q1 2024 earnings estimates for shares of OptiNose in a research report issued to clients and investors on Monday, April 29th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($0.11) per shApril 29, 2024 | bizjournals.comAfter key Xhance approval, Optinose outlines plan to quadruple sales and reach profitabilityApril 29, 2024 | marketbeat.comOptiNose's (OPTN) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of OptiNose in a report on Monday.April 27, 2024 | finance.yahoo.comOptiNose, Inc. (OPTN)April 25, 2024 | investorplace.comWhy Is OptiNose (OPTN) Stock Up 12% Today?April 25, 2024 | globenewswire.comOptinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionApril 7, 2024 | msn.comOptinose to Present at Needham Virtual Healthcare ConferenceApril 6, 2024 | finance.yahoo.comOptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years agoApril 4, 2024 | globenewswire.comOptinose to Present at the Needham Virtual Healthcare ConferenceMarch 20, 2024 | insidertrades.comMichael F. Marino III Sells 15,059 Shares of OptiNose, Inc. (NASDAQ:OPTN) StockMarch 19, 2024 | marketbeat.comInsider Selling: OptiNose, Inc. (NASDAQ:OPTN) Insider Sells 15,059 Shares of StockOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) insider Michael F. Marino III sold 15,059 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $1.88, for a total value of $28,310.92. Following the transaction, the insider now directly owns 602,268 shares in the company, valued at $1,132,263.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.March 18, 2024 | marketbeat.comOptiNose (NASDAQ:OPTN) Price Target Raised to $4.00Lake Street Capital raised their target price on OptiNose from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Monday.March 16, 2024 | finanznachrichten.deOptinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsMarch 16, 2024 | msn.comOptiNose granted FDA nod to expand labeling for sinusitis therapyMarch 15, 2024 | bizjournals.comBucks County's Optinose wins FDA approval for wider use of flagship productMarch 15, 2024 | globenewswire.comXHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsMarch 15, 2024 | marketbeat.comTrading was temporarily halted for "OPTN" at 03:03 PM with a stated reason of "News pending."March 13, 2024 | bizjournals.comOptinose primed for FDA ruling on Xhance that could 'reshape' its futureMarch 11, 2024 | marketbeat.comOptiNose (NASDAQ:OPTN) Coverage Initiated by Analysts at HC WainwrightHC Wainwright assumed coverage on shares of OptiNose in a research report on Monday. They issued a "buy" rating and a $5.00 price objective for the company.March 10, 2024 | finance.yahoo.comUS$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest ResultsMarch 10, 2024 | seekingalpha.comOptiNose, Inc. (OPTN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comOptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | marketbeat.comOptiNose (NASDAQ:OPTN) Announces Quarterly Earnings ResultsOptiNose (NASDAQ:OPTN - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $19.87 million during the quarter, compared to analyst estimates of $19.90 million. During the same quarter in the prior year, the business earned ($0.17) earnings per share.March 8, 2024 | finance.yahoo.comOptiNose Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...March 7, 2024 | investorplace.comOPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023March 7, 2024 | finanznachrichten.deOptinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 7, 2024 | finance.yahoo.comOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 7, 2024 | msn.comOptiNose reports mixed results; initiates Q1 and FY24 outlookMarch 7, 2024 | washingtonpost.comOptiNose: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 6, 2024 | benzinga.comOptiNose's Earnings: A PreviewMarch 1, 2024 | marketbeat.comOptiNose (OPTN) Scheduled to Post Earnings on ThursdayOptiNose (NASDAQ:OPTN) will be releasing earnings before the market opens on Thursday, March 7, Zacks reports.February 29, 2024 | globenewswire.comOptinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsFebruary 29, 2024 | entrepreneur.com3 Pharma Stocks to Consider for March GainsJanuary 18, 2024 | finance.yahoo.comOptinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In PracticeDecember 20, 2023 | marketbeat.comRamy A. Mahmoud Sells 11,114 Shares of OptiNose, Inc. (NASDAQ:OPTN) StockOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) CEO Ramy A. Mahmoud sold 11,114 shares of the business's stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $1.15, for a total transaction of $12,781.10. Following the sale, the chief executive officer now owns 509,728 shares of the company's stock, valued at $586,187.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.December 6, 2023 | msn.comWhy ENT-Focused OptiNose Shares Are Diving TodayDecember 6, 2023 | finance.yahoo.comOptinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCENovember 22, 2023 | finance.yahoo.comOptinose to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 18, 2023 | morningstar.comOptiNose Inc OPTN Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this chart look familiar? (Ad)Investors who understand when to get in — and when to get out… Can make a lot of money. Like in the chart, I showed you above… Get all the information here. OPTN Media Mentions By Week OPTN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPTN News Sentiment▼0.170.57▲Average Medical News Sentiment OPTN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPTN Articles This Week▼91▲OPTN Articles Average Week Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Societal CDMO News Rezolute News Relmada Therapeutics News Cellectar Biosciences News PMV Pharmaceuticals News Coya Therapeutics News Cartesian Therapeutics News Citius Pharmaceuticals News Immunic News Allakos News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPTN) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe only AI company you should be looking atBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
